Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
From 2023 to 2025, MedStar Health served as a research site for the ATTAIN-1 trial, a phase III double-blind, placebo-controlled study of the safety and efficacy of the GLP-1 receptor agonist drug orforglipron
The SUSTAIN and SELECT trials provided long-term safety data spanning multiple years
Your provider will review all available options and help you choose the treatment plan that fits your medical needs and budget
One of the possible unwanted side effects of eating less while on semaglutide is losing too much muscle in addition to fat
Shared decision-making between clinician and patient is essential when choosing between these agents
US$ 25.70
US$ 26.45
US$ 28.99
US$ 24.77
